November 14, 2019

Clinical Data Showing The Potential Of Epeleuton As A Treatment For Hypertriglyceridemia And Diabetes As Well As Cardiovascular Disease Prevention Will Be Presented At The American Heart Association’s 2019 Scientific Sessions, November 16-18

Dublin, Ireland, 14th November 2019 – Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that results of its investigational drug Epeleuton will be presented at […]
December 18, 2018

Afimmune receives method of use patent allowance for Oral AF102 in the US

Dublin, Ireland, 18th December 2018 – Afimmune, a privately held clinical stage drug discovery and development company, today announced receipt of allowance for a patent application in […]